DK0737686T3 - Camthothecinderivat med antitumoraktivitet - Google Patents

Camthothecinderivat med antitumoraktivitet

Info

Publication number
DK0737686T3
DK0737686T3 DK96105661T DK96105661T DK0737686T3 DK 0737686 T3 DK0737686 T3 DK 0737686T3 DK 96105661 T DK96105661 T DK 96105661T DK 96105661 T DK96105661 T DK 96105661T DK 0737686 T3 DK0737686 T3 DK 0737686T3
Authority
DK
Denmark
Prior art keywords
compound
camthothecin
derivatives
antitumor activity
formula
Prior art date
Application number
DK96105661T
Other languages
Danish (da)
English (en)
Inventor
Hirofumi Terasawa
Shinji Kamihara
Kazuaki Kanai
Hiroaki Kitaoka
Original Assignee
Daiichi Seiyaku Co
Yakult Honsha Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co, Yakult Honsha Kk filed Critical Daiichi Seiyaku Co
Application granted granted Critical
Publication of DK0737686T3 publication Critical patent/DK0737686T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK96105661T 1995-04-10 1996-04-10 Camthothecinderivat med antitumoraktivitet DK0737686T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8371795 1995-04-10

Publications (1)

Publication Number Publication Date
DK0737686T3 true DK0737686T3 (da) 1999-11-22

Family

ID=13810270

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96105661T DK0737686T3 (da) 1995-04-10 1996-04-10 Camthothecinderivat med antitumoraktivitet

Country Status (13)

Country Link
US (2) US6504029B1 (zh)
EP (1) EP0737686B1 (zh)
KR (1) KR100400941B1 (zh)
CN (1) CN1050131C (zh)
AT (1) ATE181919T1 (zh)
CA (1) CA2173671A1 (zh)
DE (1) DE69603117T2 (zh)
DK (1) DK0737686T3 (zh)
EA (1) EA000036B1 (zh)
ES (1) ES2136338T3 (zh)
GR (1) GR3031400T3 (zh)
NO (1) NO314085B1 (zh)
TW (1) TW382630B (zh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1278518T3 (da) 2000-02-28 2007-01-15 Pfizer Entpr Sarl Synergistisk kombination til behandling af colorektal cancer
US6548488B2 (en) 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
AR030207A1 (es) * 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
KR100742524B1 (ko) 2000-10-27 2007-08-02 아방티 파르마 소시에테 아노님 캄프토테신과 스틸벤 유도체를 포함하는 암 치료용 약제학적 병용제제
WO2006069344A2 (en) 2004-12-22 2006-06-29 Rutgers, The State University Of New Jersey Controlled release hydrogels
JP5313867B2 (ja) 2006-03-30 2013-10-09 ドライス ファーマシューティカルズ，インコーポレイティド カンプトテシン−細胞透過性ペプチド複合体及びそれを含む医薬組成物
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
US20140086975A1 (en) 2010-10-15 2014-03-27 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
KR102087017B1 (ko) * 2012-10-11 2020-03-10 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
EP3088419B1 (en) 2013-12-25 2018-10-10 Daiichi Sankyo Company, Limited Anti-trop2 antibody-drug conjugate
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
US11185594B2 (en) 2014-04-10 2021-11-30 Daiichi Sankyo Company, Limited (Anti-HER2 antibody)-drug conjugate
CN111228511B (zh) 2014-04-10 2024-06-18 第一三共株式会社 抗her3抗体-药物偶联物
BR112017027690A2 (pt) 2015-06-29 2018-10-09 Daiichi Sankyo Co Ltd “método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco
EP3552626A4 (en) 2016-12-12 2020-06-10 Daiichi Sankyo Company, Limited ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR
JP6679762B2 (ja) 2017-01-17 2020-04-15 第一三共株式会社 抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体−薬物コンジュゲート
TW202330036A (zh) 2017-05-15 2023-08-01 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
CN117838880A (zh) 2017-08-31 2024-04-09 第一三共株式会社 制备抗体-药物缀合物的新方法
EP3677589A4 (en) 2017-08-31 2021-04-21 Daiichi Sankyo Company, Limited IMPROVED PROCESS FOR PREPARING ANTIBODY-ACTIVE CONJUGATE
CN117815404A (zh) 2018-05-18 2024-04-05 第一三共株式会社 抗-muc1抗体-药物缀合物
MX2021003382A (es) 2018-09-26 2021-05-27 Jiangsu Hengrui Medicine Co Conjugado de ligando y farmaco analogo de exatecan, metodo de preparacion del mismo y aplicacion del mismo.
AU2019351427A1 (en) 2018-09-30 2021-04-15 Changzhou Hansoh Pharmaceutical Co., Ltd. Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof
CN118240003A (zh) 2019-03-29 2024-06-25 免疫医疗有限公司 化合物及其缀合物
MX2022000450A (es) 2019-07-10 2022-04-25 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.
EP3997093A1 (en) 2019-07-10 2022-05-18 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
EP4074345A4 (en) 2019-12-12 2023-10-25 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTI-CLAUDINE ANTIBODY-DRUG CONJUGATE AND ITS PHARMACEUTICAL USE
EP4095148A4 (en) 2020-01-22 2023-07-26 Jiangsu Hengrui Medicine Co., Ltd. ANTI-TROP-2 ANTIBODY EXATECAN ANALOGUE CONJUGATE AND MEDICAL USE THEREOF
CN115103858A (zh) 2020-03-25 2022-09-23 江苏恒瑞医药股份有限公司 一种抗体药物偶联物的制备方法
CN115298186A (zh) 2020-03-25 2022-11-04 江苏恒瑞医药股份有限公司 抗psma抗体-依喜替康类似物偶联物及其医药用途
TW202144013A (zh) 2020-03-25 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 一種含抗體藥物偶聯物的醫藥組成物及其用途
WO2023030364A1 (zh) * 2021-09-01 2023-03-09 上海弼领生物技术有限公司 一种喜树碱类化合物、其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6087746A (ja) * 1983-10-17 1985-05-17 Hakubakumai Kk 即席麺ないしは焼そば用蒸し麺の製造方法
US4939255A (en) * 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
US5658920A (en) * 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
JP3008226B2 (ja) * 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
IS4152A (is) * 1993-04-29 1994-10-30 Glaxo Inc. Vatnsuppleysanlegar Camptothecin afleiður og aðferð til framleiðslu þeirra
GB9319944D0 (en) * 1993-09-28 1993-11-17 Erba Carlo Spa Process for the preparation of 9-amino camptothecin

Also Published As

Publication number Publication date
NO314085B1 (no) 2003-01-27
NO961405L (no) 1996-10-11
CN1050131C (zh) 2000-03-08
CA2173671A1 (en) 1996-10-11
EA199600018A3 (ru) 1997-03-31
KR100400941B1 (ko) 2003-12-24
US6552197B2 (en) 2003-04-22
US20010034446A1 (en) 2001-10-25
DE69603117D1 (de) 1999-08-12
EA199600018A2 (ru) 1996-10-01
EP0737686B1 (en) 1999-07-07
GR3031400T3 (en) 2000-01-31
ATE181919T1 (de) 1999-07-15
EA000036B1 (ru) 1998-02-26
AU692078B2 (en) 1998-05-28
CN1133290A (zh) 1996-10-16
AU5056696A (en) 1996-10-24
NO961405D0 (no) 1996-04-09
KR960037682A (ko) 1996-11-19
TW382630B (en) 2000-02-21
ES2136338T3 (es) 1999-11-16
US6504029B1 (en) 2003-01-07
DE69603117T2 (de) 1999-10-28
EP0737686A1 (en) 1996-10-16

Similar Documents

Publication Publication Date Title
DK0737686T3 (da) Camthothecinderivat med antitumoraktivitet
DE69327567D1 (de) Verfahren zur Herstellung von Alanylglutamin
FR2383907A1 (fr) Procede de preparation de derives de l'acide acetique et derives obtenus par ce procede
NO882588D0 (no) Fremgangsmaate ved fremstilling av substituerte inololinonderivater.
BG95145A (bg) Метод за получаване на 9-заместени гуанинови производни
KR880700793A (ko) 퀴놀린 카복실산의 제조 방법
DE69809888T2 (de) Verfahren zur Herstellung von alpha-Aminoketonen
DK159432C (da) Fremgangsmaade til fremstilling af 4-amino-5-dialkoxymethylpyrimidinderivater
ATE18208T1 (de) N-(4-hydroxyphenyl)essigsaeureamid-estern aus 5benzoyl-1-methylpyrrol-2-essigsaeure.
SE8503811D0 (sv) Novel process for the preparation of an aminolactone
ATE57934T1 (de) Verfahren zur herstellung von griseolinsaeurederivaten.
ES2104612T3 (es) Procedimiento de preparacion de derivados de sulfonamida de norbornano.
ATE100105T1 (de) Physiologisch aktive substanz fa-4283, derivate und ihre herstellung.